Bob,

I've had a very busy week, but I hope to give it a good look today. The one thing that I did notice though was the assumption regarding T2s currently using oral medications only. You made the assumption that they would only use Afrezza at a 50% rate compared to patients already using insulin. I would dispute this as Affrezza is intended as a prandial insulin. So anyone initiated on it would likely be prescribed a TID (3 times a day) dose. So I would assign a value of $2000 per year for each of these patients as well.

If I remember right, in the studies, they do have 2 dosing levels. But for many drugs, the price is not related to the dose - which is why we often have patients split pills to save money.